| abstract |
An OSPA chimera and its use in a vaccine are provided. The present invention relates to the development of chimeric OspA molecules for use in novel lime vaccines. More specifically, a chimeric OspA molecule contains a proximal portion from one OspA serotype along with a distal portion from another OspA serotype, and retains the antigenic properties of both parent polypeptides. Chimeric OspA molecules are delivered alone or in combination to provide protection against various Borrelia genotypes. [Selection figure] None |